实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (1): 107-110.doi: 10.3969/j.issn.1672-5069.2021.01.028

• 肝癌 • 上一篇    下一篇

XELOX联合贝伐珠单克隆抗体方案转化治疗同时性结肠癌并发肝转移患者初步研究

张华, 孙宝峰, 刘世祺   

  1. 273500 山东省邹城市兖矿新里程总医院消化内科(张华,孙宝峰);
    济宁医学院附属医院胃肠外科(刘世祺)
  • 出版日期:2021-01-10 发布日期:2021-01-19
  • 通讯作者: 张华,男,37岁,大学本科,副主任医师
       通讯作者:孙宝峰,E-mail:sbfzhxiao@163.com
  • 作者简介:张华,男,37岁,大学本科,副主任医师

Combination of oxaliplatin and capecitabine plus bevacizumab in conversion treatment of patients with colon cancer and liver metastasis

Zhang Hua, Sun Baofeng, Liu Shiqi   

  1. Department of Gastroenterology, Yankuang New Mileage General Hospital, Zoucheng 273500,Shandong Province, China
  • Online:2021-01-10 Published:2021-01-19

摘要: 目的 探讨应用奥沙利铂和卡培他滨(XELOX)联合贝伐珠单克隆抗体方案转化治疗同时性结肠癌并发肝转移患者疗效及安全性。方法 2015年6月~2017年7月我院诊治的41例初始不可切除的结肠癌并发肝转移患者,实施了XELOX联合贝伐珠单克隆抗体方案的转化治疗,观察了转化治疗应答率、转化结果、不良反应和总生存期(OS)。结果 41例初始不可切除的结肠癌并发肝转移患者均接受了不少于4个疗程的转化治疗。在转化治疗后,31例(75.6%)患者呈部分缓解(PR),其中14例(34.1%)患者接受了根治性手术;在转化治疗后随访13~26个月(中位随访时间为18个月),转化手术组与未手术组1 a总生存率分别为92.3%(失访1例)和66.7%,经Log-rank 检验发现转化手术组患者总生存期显著长于未手术组(P=0.019)。结论 应用贝伐珠单克隆抗体联合XELOX方案治疗同时性结肠癌并发肝转移患者安全有效,部分初始不可切除患者可以通过转化治疗再次获得手术机会,而一旦实施转化手术,有望延长患者的生存时间。

关键词: 肝转移癌, 结肠癌, 贝伐珠单克隆抗体, 转化治疗, 生存

Abstract: Objective To explore the efficacy and safety of combination of oxaliplatin and capecitabine (XELOX) plus bevacizumab in conversion treatment of patients with colon cancer and liver metastasis. Methods A total of 41 patients with de novo unresectable colon cancer and liver metastases were enrolled in our hospital between June 2015 and July 2017, and all patients underwent XELOX and bevacizumab for conversion therapy. The response rate, conversion surgical rate and overall survival time (OS) were observed. Results All patients finished at least four courses of conversion therapy, and 31 patients (75.6%) had partial response, 14 patients (34.1%) underwent radical surgery after conversion treatment; 40 patients were followed up for 13 to 26 months with the medium of 18 months and one patient after radical surgery lost, and one-year survival at radical surgery and non-surgery group were 92.3% and 66.7%, which showed significantly difference by Log-rank testing (P=0.019).Conclusion The administration of bevacizumab plus XELOX regimen is safe and efficacious in the conversion treatment of patients with colon cancer and simultaneous liver metastases, and parts of patients might obtain opportunity for radical surgery, which is expected to prolong the survival time.

Key words: Liver metastases, Colon cancer, Bevacizumab, Conversion therapy, Survival